Patients with resected stage III and IV melanoma have a high risk of recurrence. As the outcomes for patients with metastatic disease have improved dramatically over the last decade due …
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
Guidelines for pathologic evaluation of neoadjuvant specimens and pathologic response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC). As part of the OpACIN-neo clinical trial of neoadjuvant …